Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab + Daratumumab + Lenalidomide in Newly Diagnosed Multiple Myeloma
NCT05623020Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Nov 2022
- Primary completion
- Oct 2030
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial of elranatamab in multiple myeloma (MM) (5 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicity at 28 days, Progression Free Survival at 97 months and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05623020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05623020.